South Dakota voters rejected Amendment I, which could have ended Medicaid expansion for approximately 31,000 residents if federal funding fell below 90%.
News|Articles|April 1, 2003
Update on the treatment of osteoporosis
Osteoporosis affects more than 10 million Americans and accounts for 1.5 million fractures annually. Several treatment options have been shown to prevent fractures and improve outcomes in patients with osteoporosis. Alendronate and risedronate clearly reduce fractures and are good initial choices in many patients. Raloxifene and calcitonin reduce the risk of vertebral fractures and may be appropriate in certain patients. Teriparatide was recently approved by FDA for the treatment of osteoporosis and may offer another treatment option. Combination therapy has been shown to increase bone mineral density; however, a reduction in the risk of fractures remains to be established. Zoledronic acid may offer an advantage of reduced frequency of administration.
Advertisement
Advertisement
Related to this article
Christine Johnston says Medicaid plans have embraced biosimilars faster than commercial plans and challenges the idea that more expensive means better.
After more than 20 years at Humana, Jeremy Gaskill now leads nonprofit Geisinger Health Plan. The problems are the same, he says, the scale for solving them differs.
Jeremy Gaskill took the reins at the Geisinger Health Plan earlier this year after a long career at Humana. He discusses the similarities and differences between Geisinger and Humana and the advantages of a health plan that is part of a health system.
The retail pharmacies will be in one company and Aetna and CVS Caremark, the PBM, in another, according to news reports.
Swedish registry study links parents’ autoimmune diseases to higher childhood type 1 diabetes risk, suggesting shared genetic susceptibility beyond pregnancy effects.
Christine Johnston warns a thin biosimilar pipeline keeps specialty costs high and slows innovation and urges payers to check their PBM’s top 25 drugs.
Speakers and researchers at this year's meeting in San Diego focused on drug pricing policy, getting savings to patients at the pharmacy counter and keeping people in charge of AI.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
CVS Health is splitting in two, according to news reports
2
Jeremy Gaskill on moving from Humana to Geisinger Health Plan
3
South Dakota voters reject Medicaid expansion trigger amendment
4
On the advantages of health system-owned health plan, what Medicaid cuts might mean and the future of U.S. health insurance: A conversation with Geisinger's Jeremy Gaskill
5